DeCure's autonomous Immuno AI scientist is researching a drug-repurposing hypothesis for inflammatory bowel disease 10 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleInflammatory bowel disease 10 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for inflammatory bowel disease 10 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
autophagy related 16 like 1 (ATG16L1) — ATG16L1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet r,rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5NUV · 1.55 Å · ligand (R,R)-2,3-BUTANEDIOL (BU3). Experimental structure, not a prediction.
What the evidence adds up to
In a 1998 murine model of dextran sulfate sodium-induced colitis, tissue levels of tumour necrosis factor-alpha and interleukin-1beta rose in a time-dependent manner after colitis induction, followed by a peak of interleukin-10. Adding interleukin-10 to cultured colonic tissues inhibited production of tumour necrosis factor-alpha and interleukin-1beta, while anti-interleukin-10 antibodies enhanced it. Treatment with interleukin-10 produced a marked improvement in intestinal inflammation; blocking endogenous interleukin-10 caused a modest exacerbation. The authors concluded that interleukin-10 has a functional role in regulating colonic inflammation in that model.
A 2002 review noted that advances in treating inflammatory bowel disease included 5-aminosalicylic preparations with fewer adverse effects, new rapidly metabolised corticosteroids, and agents targeted at refractory or complicated disease. It stressed the need for individualised treatment but gave no quantitative outcomes. A 1980 report of 100 patients treated for one to 15 years gave relative rates of operation: 11 per cent of chronic ulcerative colitis patients had major procedures, and 36 per cent of Crohn’s disease patients. That series suggested reduced operation rates compared with earlier reports.
A 2024 review stated that inflammatory bowel disease is incurable, that management is not unanimous because patients react differently to treatment, and that the search for new therapeutic targets is continuous. It listed various therapeutic targets but provided no new clinical data, no response rates, and no survival figures.
What is still missing: controlled human trials of interleukin-10 in inflammatory bowel disease with adequate sample sizes; a trial design that accounts for the variable patient responses noted in the 2024 review; and funding to move beyond murine models and narrative reviews into stratified, randomised studies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Scandinavian Journal of Gastroenterology · 1998 · 107 citations
Role of Interleukin-10 in a Murine Model of Dextran Sulfate Sodium-Induced Colitis
AbstractBACKGROUND: Increased production of proinflammatory cytokines is characteristic of both animal models of experimental colitis and human inflammatory bowel disease. This study was designed to characterize the functional role of interleukin (IL)-10 in a murine model of experimental colitis. METHODS: Cytokine profiles were analyzed in animals with dextran sulfate sodium-induced colitis. The effect of treatment with IL-10 or anti-IL-10 antibodies on colonic cytokine production in vitro and tissue damage in vivo were evaluated. RESULTS: After the induction of colitis, there was a time-dependent increase in tissue tumor necrosis factor-alpha and IL-1beta levels, followed by a peak of the IL-10 level. The production of tumor necrosis factor-alpha and IL-1beta by cultured colonic tissues was inhibited by addition of IL-10, and conversely, it was enhanced by anti-IL-10. Treatment with IL-10 resulted in a marked improvement in intestinal inflammation. Blocking endogenous IL-10 was found to cause a modest exacerbation of inflammation. CONCLUSIONS: These results show that IL-10 has a functional role in regulating colonic inflammation during experimental colitis.
AbstractAdvances in the treatment of inflammatory bowel disease (IBD) in the past decade include 5-aminosalicylic preparations with fewer adverse effects; new, rapidly metabolized corticosteroids; and new agents targeted at refractory or complicated IBD. Dr Tung and Dr Warner discuss the use of these and more traditional drugs in patients with colonic Crohn's disease and ulcerative colitis, stressing the need for individualized treatment.
Revista de historiografía (RevHisto) · 2009 · 0 citations
Erasmo (1476?-1536) y la filología del Nuevo Testamento
AbstractExperience in treating 100 patients with inflammatory bowel disease, for periods ranging from one to 15 years, is reviewed. A concise clinical classification of inflammatory bowel disease, correlated with a method of management, is presented. Relative rates of operation appear to be reduced over previously reported series: among chronic ulcerative colitis patients, 11 per cent had major precedures; for Crohn's disease, 36 per cent.
Diseases of the Colon & Rectum · 1980 · 0 citations
Management of inflammatory bowel disease
AbstractExperience in treating 100 patients with inflammatory bowel disease, for periods ranging from one to 15 years, is reviewed. A concise clinical classification of inflammatory bowel disease, correlated with a method of management, is presented. Relative rates of operation appear to be reduced over previously reported series: among chronic ulcerative colitis patients, 11 per cent had major precedures; for Crohn's disease, 36 per cent.
Zenodo (CERN European Organization for Nuclear Research) · 2024 · 0 citations · open access
Therapeutic Targets Associated with Medical Research in the Treatment of Inflammatory Bowel Disease
AbstractInflammatory bowel disease (IBD) is a multifactorial disease of the digestive tract. Their prevalence has increased considerably in the previous decade due to industrialization and changes in people's lifestyles. These are incurable diseases whose management is not unanimous because patients react differently to the treatment administered. Therefore, the search for new therapeutic targets is continuous to find better treatment, to reduce the periods of crisis and to improve the health of the patients. In view of this fact, we have in this article brought together the various therapeutic targets associated with these pathologies to produce effective care against inflammatory bowel diseases.
AbstractThis chapter presents information on etiology/pathophysiology, signalment/history, clinical features, differential diagnosis, diagnostics and therapeutics of inflammatory bowel disease in cats and dogs. Inflammatory bowel disease is a diagnosis of exclusion to be primarily differentiated from food-responsive enteropathy, antibiotic-responsive enteropathy, and intestinal cancer. Inflammatory bowel disease is generally characterized by the predominant mucosal cellular infiltrate, such as lymphocytic-plasmacytic, eosinophilic, or granulomatous enterocolitis. Cats with inflammatory bowel disease may show alterations in serum total protein with increased liver enzyme activities. Definitive diagnosis of inflammatory bowel disease requires intestinal biopsy and histopathology, usually obtained via gastrointestinal endoscopy. Evidence-based data indicate that glucocorticoids are effective drugs for inducing remission in the majority of dogs and cats. Empirical use of other immunosuppressive drugs, including azathioprine, chlorambucil, leflunomide, and mycophenolate, for treatment of inflammatory bowel disease has been reported.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
